Amigas 
Rifafit-400
Rifaximin 400 mg · Tablet
Gut-selective antibiotic for the management of traveller's diarrhoea and hepatic encephalopathy with minimal systemic absorption.
About Rifafit-400
Rifafit-400 is an oral tablet formulation of Rifaximin 400 mg developed by Amigas Pharma. Rifaximin is a semi-synthetic, non-systemic antibiotic that acts locally in the gastrointestinal tract with minimal absorption into the bloodstream, making it a gut-selective option in appropriate clinical settings. It is used under medical supervision for indications such as traveller's diarrhoea caused by non-invasive strains of Escherichia coli and the reduction in recurrence of overt hepatic encephalopathy in adults with liver disease. Each Rifafit-400 tablet is manufactured at a WHO-GMP certified facility with validated processes covering active ingredient assay, dissolution, and stability testing.
Composition
| Ingredient | Strength | Role |
|---|---|---|
| Rifaximin | 400 mg | Gut-selective, non-systemic antibiotic acting locally in the intestine with minimal systemic absorption; used under medical supervision for traveller's diarrhoea and hepatic encephalopathy. |
Product specifications
- Brand name
- Rifafit-400
- Generic name
- Rifaximin
- Dosage form
- Tablet
- Packaging
- 10 x 1 x 10 Tablets
- Category
- Antibiotic
- Therapy area
- Gastroenterology
Storage & handling
Store below 25°C in a dry place, protected from direct light and moisture. Keep out of the reach and sight of children. Do not use after the expiry date printed on the pack.
Prescribing information
This product is for use under the supervision of a registered medical practitioner. Please refer to the full prescribing information supplied with the pack insert for indications, dosage, contraindications, warnings and adverse events. Report any adverse events to your physician or to Amigas Pharma.
